Replacing Injections with Oral Therapeutics
Intract Pharma (intractpharma.com) scores 72 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, Technology brands, in the 32nd percentile of 19911 Healthcare brands.
Intract Pharma is a biopharmaceutical technology company that develops proprietary colonic and gastrointestinal drug delivery platforms, including Soteria and Phloral, designed to enable biologic drugs such as monoclonal antibodies to be administered orally instead of by injection. The company partners with pharmaceutical and biotechnology firms seeking to convert injectable biologics into oral tablets or capsules, aiming to improve patient care through safer, more convenient treatment options for patients who currently require injectable biologic therapies.
| Brand Name | Intract Pharma |
|---|---|
| Domain | intractpharma.com |
| Industry | Healthcare, Technology |
| Main Competitors | Rani Therapeutics (68/100), Oramed Pharmaceuticals (79/100), Entera Bio, Applied Molecular Transport (47/100), Enteris BioPharma (83/100) |
Moz Domain Authority 23/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Transforming Patient Care by Replacing Injections with Safer, More Effective Therapeutics Given Orally." (Meta description: 13 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Breadcrumb/Website schema, + Microdata, og:title, og:description, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on X (Twitter), Facebook, Instagram; no detected presence on LinkedIn, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Intract Pharma?", Claude could identify the brand as of October 2026. Intract Pharma is a UK-based biotech company, spun out of University College London, that develops oral drug delivery technologies aimed at enabling biologics and peptides, which normally require injection, to be taken as pills by protecting them through the gut and targeting rel Best known for Developing oral delivery platforms for biologic drugs and peptides, allowing injectable medicines to potentially be taken as pills.
When asked "Best brands similar to Intract Pharma?", Claude would recommend Intract Pharma as of October 2026. It's a notable player in the oral biologics delivery space, so I'd mention it alongside other companies working on making injectable drugs available in pill form.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Intract Pharma's main competitors in Healthcare: Rani Therapeutics (68/100), Oramed Pharmaceuticals (79/100), Applied Molecular Transport (47/100), Enteris BioPharma (83/100).
Sources: Brand Analyzer scan
Intract Pharma has low AI-search visibility, scoring 20/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 32, recommendation 42). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Intract Pharma official site
Intract Pharma offers proprietary drug delivery technologies, specifically Soteria and Phloral, which are designed to target the colon and gastrointestinal tract. These technologies enable biologic drugs, such as monoclonal antibodies, to be formulated and administered as oral tablets or capsules instead of injections, intended for use by pharmaceutical and biotechnology companies developing biologic therapeutics.
Sources: Intract Pharma official site
Intract Pharma scores 42/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Intract Pharma official site
Intract Pharma is a biopharmaceutical technology company focused on drug delivery innovation. It develops proprietary colonic and gastrointestinal drug delivery technologies, such as Soteria and Phloral, that allow biologic drugs like monoclonal antibodies to be formulated as oral tablets or capsules rather than injections. The company works with pharmaceutical and biotechnology partners to apply these technologies to their biologic drug candidates, with the goal of transforming patient care by replacing injections with safer, more effective oral therapeutics.
Sources: Intract Pharma official site
Intract Pharma develops drug delivery platforms, including Soteria and Phloral, that target the colon and gastrointestinal tract to enable oral administration of biologic drugs such as monoclonal antibodies. The company partners with pharmaceutical and biotechnology companies to convert their injectable biologic drugs into oral formulations, aiming to improve treatment convenience and safety for patients who currently rely on injections.
Sources: Intract Pharma official site
Intract Pharma can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Intract Pharma official site
Intract Pharma is known for developing proprietary oral drug delivery technologies, Soteria and Phloral, which target the colon and gastrointestinal tract to enable biologic drugs, including monoclonal antibodies, to be administered as oral tablets or capsules rather than injections.
Sources: Intract Pharma official site
Intract Pharma's technologies are used by pharmaceutical and biotechnology companies seeking to convert their injectable biologic drugs into oral formulations. Indirectly, patients who require biologic treatments, such as monoclonal antibodies, and who could benefit from non-injectable alternatives are also a target group served through these pharmaceutical partnerships.
Sources: Intract Pharma official site
Intract Pharma scores 20/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Intract Pharma has a weak AI-visibility profile at 20/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (42/100) and its weakest is visibility (0/100). It benefits from open access for AI crawlers (GPTBot, ClaudeBot, etc.) and machine-readable schema.org markup. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 23/100. In a live check, Claude could already identify Intract Pharma from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Intract Pharma: Interoptik (72/100), IntelliCentrics (72/100), IO Health (72/100), International Pediatric Association (IPA) (72/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.